Standard BioTools (LAB) Competitors

$1.00 +0.01 (+0.80%)

Closing price 03:59 PM Eastern

Extended Trading

$1.00 +0.00 (+0.30%)

As of 06:49 PM Eastern

LAB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

Should you buy Standard BioTools stock or one of its competitors? MarketBeat compares Standard BioTools with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Standard BioTools include Alamar Biosciences (ALMR), Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.

How does Standard BioTools compare to Alamar Biosciences?

Standard BioTools (NASDAQ:LAB) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

53.7% of Standard BioTools shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alamar Biosciences has higher revenue and earnings than Standard BioTools.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.56	-$74.90M	$0.20	4.99
Alamar Biosciences	$87.16M	16.31	N/A	N/A	N/A

Standard BioTools presently has a consensus target price of $1.35, indicating a potential upside of 35.41%. Alamar Biosciences has a consensus target price of $30.00, indicating a potential upside of 46.27%. Given Alamar Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Alamar Biosciences is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Standard BioTools has a net margin of 73.46% compared to Alamar Biosciences' net margin of 0.00%. Alamar Biosciences' return on equity of 0.00% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Alamar Biosciences	N/A	N/A	N/A

In the previous week, Alamar Biosciences had 7 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Alamar Biosciences and 0 mentions for Standard BioTools. Alamar Biosciences' average media sentiment score of 0.66 beat Standard BioTools' score of 0.00 indicating that Alamar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
Alamar Biosciences	Positive

Summary

Alamar Biosciences beats Standard BioTools on 9 of the 12 factors compared between the two stocks.

How does Standard BioTools compare to Allient?

Allient (NASDAQ:ALNT) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Allient has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Standard BioTools has a net margin of 73.46% compared to Allient's net margin of 4.25%. Allient's return on equity of 12.47% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Standard BioTools	73.46%	-8.18%	-6.43%

In the previous week, Allient had 3 more articles in the media than Standard BioTools. MarketBeat recorded 3 mentions for Allient and 0 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.00 beat Allient's score of -0.48 indicating that Standard BioTools is being referred to more favorably in the news media.

Company	Overall Sentiment
Allient	Neutral
Standard BioTools	Neutral

Allient presently has a consensus price target of $72.25, indicating a potential upside of 18.44%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 35.41%. Given Standard BioTools' higher possible upside, analysts plainly believe Standard BioTools is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

61.6% of Allient shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 15.0% of Allient shares are owned by company insiders. Comparatively, 23.2% of Standard BioTools shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Allient has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	1.87	$22.03M	$1.43	42.66
Standard BioTools	$85.33M	4.56	-$74.90M	$0.20	4.99

Summary

Allient beats Standard BioTools on 11 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Standard BioTools (NASDAQ:LAB) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Standard BioTools has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

In the previous week, Eyepoint Pharmaceuticals had 4 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 0 mentions for Standard BioTools. Eyepoint Pharmaceuticals' average media sentiment score of 0.10 beat Standard BioTools' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
Eyepoint Pharmaceuticals	Neutral

Standard BioTools has a net margin of 73.46% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Standard BioTools' return on equity of -8.18% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	73.46%	-8.18%	-6.43%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 23.2% of Standard BioTools shares are owned by insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Standard BioTools has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	4.56	-$74.90M	$0.20	4.99
Eyepoint Pharmaceuticals	$31.37M	31.59	-$231.96M	-$3.50	N/A

Standard BioTools currently has a consensus price target of $1.35, indicating a potential upside of 35.41%. Eyepoint Pharmaceuticals has a consensus price target of $31.80, indicating a potential upside of 169.04%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Eyepoint Pharmaceuticals beats Standard BioTools on 9 of the 17 factors compared between the two stocks.

How does Standard BioTools compare to Transcat?

Transcat (NASDAQ:TRNS) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Transcat has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

98.3% of Transcat shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 2.8% of Transcat shares are held by company insiders. Comparatively, 23.2% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Transcat had 2 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for Transcat and 0 mentions for Standard BioTools. Transcat's average media sentiment score of 0.00 equaled Standard BioTools'average media sentiment score.

Company	Overall Sentiment
Transcat	Neutral
Standard BioTools	Neutral

Standard BioTools has a net margin of 73.46% compared to Transcat's net margin of 2.47%. Transcat's return on equity of 6.15% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Transcat	2.47%	6.15%	4.15%
Standard BioTools	73.46%	-8.18%	-6.43%

Transcat has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Transcat	$278.42M	2.33	$14.52M	$0.85	81.93
Standard BioTools	$85.33M	4.56	-$74.90M	$0.20	4.99

Transcat currently has a consensus target price of $105.33, suggesting a potential upside of 51.25%. Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 35.41%. Given Transcat's stronger consensus rating and higher possible upside, analysts clearly believe Transcat is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Transcat	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Transcat beats Standard BioTools on 12 of the 16 factors compared between the two stocks.

How does Standard BioTools compare to Frequency Electronics?

Frequency Electronics (NASDAQ:FEIM) and Standard BioTools (NASDAQ:LAB) are both small-cap measuring and control equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Frequency Electronics has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, Standard BioTools has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

58.6% of Frequency Electronics shares are owned by institutional investors. Comparatively, 53.7% of Standard BioTools shares are owned by institutional investors. 28.0% of Frequency Electronics shares are owned by insiders. Comparatively, 23.2% of Standard BioTools shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Frequency Electronics had 4 more articles in the media than Standard BioTools. MarketBeat recorded 4 mentions for Frequency Electronics and 0 mentions for Standard BioTools. Frequency Electronics' average media sentiment score of 0.46 beat Standard BioTools' score of 0.00 indicating that Frequency Electronics is being referred to more favorably in the media.

Company	Overall Sentiment
Frequency Electronics	Neutral
Standard BioTools	Neutral

Standard BioTools has a net margin of 73.46% compared to Frequency Electronics' net margin of 10.78%. Frequency Electronics' return on equity of 12.69% beat Standard BioTools' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Frequency Electronics	10.78%	12.69%	7.84%
Standard BioTools	73.46%	-8.18%	-6.43%

Frequency Electronics has higher earnings, but lower revenue than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Frequency Electronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Frequency Electronics	$69.81M	8.17	$23.69M	$0.75	77.27
Standard BioTools	$85.33M	4.56	-$74.90M	$0.20	4.99

Frequency Electronics presently has a consensus price target of $43.67, indicating a potential downside of 24.65%. Standard BioTools has a consensus price target of $1.35, indicating a potential upside of 35.41%. Given Standard BioTools' higher probable upside, analysts clearly believe Standard BioTools is more favorable than Frequency Electronics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Frequency Electronics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Frequency Electronics beats Standard BioTools on 13 of the 17 factors compared between the two stocks.

Get Standard BioTools News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LAB vs. The Competition

Export

Metric	Standard BioTools	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$386.11M	$1.42B	$6.25B	$12.23B
Dividend Yield	N/A	N/A	2.80%	5.32%
P/E Ratio	4.99	65.26	20.79	25.05
Price / Sales	4.56	6.01	531.21	72.69
Price / Cash	N/A	22.74	43.09	54.25
Price / Book	0.69	5.91	9.81	6.83
Net Income	-$74.90M	-$54.76M	$3.55B	$335.69M
7 Day Performance	-1.29%	1.19%	-2.07%	-2.03%
1 Month Performance	7.22%	4.84%	-3.90%	-1.90%
1 Year Performance	-5.05%	-7.66%	29.39%	27.36%

Standard BioTools Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LAB Standard BioTools	1.6592 of 5 stars	$1.00 +0.8%	$1.35 +35.4%	-8.4%	$386.11M	$85.33M	4.99	620
ALMR Alamar Biosciences	4.7938 of 5 stars	$20.50 -1.7%	$30.00 +46.3%	N/A	$1.42B	$87.16M	N/A	222	Short Interest Increase
ALNT Allient	4.0841 of 5 stars	$59.40 -2.5%	$72.25 +21.6%	+89.2%	$1.01B	$560.59M	41.54	2,478
EYPT Eyepoint Pharmaceuticals	2.8574 of 5 stars	$11.69 -0.1%	$31.80 +172.0%	+90.9%	$983.20M	$7.61M	N/A	120
TRNS Transcat	2.3744 of 5 stars	$71.75 -7.7%	$105.33 +46.8%	-4.4%	$670.89M	$278.42M	84.60	1,245	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LAB) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Standard BioTools (LAB) Competitors

LAB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

How does Standard BioTools compare to Alamar Biosciences?

Summary

How does Standard BioTools compare to Allient?

Summary

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Summary

How does Standard BioTools compare to Transcat?

Summary

How does Standard BioTools compare to Frequency Electronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Standard BioTools (LAB) Competitors

LAB vs. ALMR, ALNT, EYPT, TRNS, and FEIM

How does Standard BioTools compare to Alamar Biosciences?

Do institutionals and insiders believe in LAB or ALMR?

Which has better valuation & earnings, LAB or ALMR?

Do analysts recommend LAB or ALMR?

Is LAB or ALMR more profitable?

Does the media favor LAB or ALMR?

Summary

How does Standard BioTools compare to Allient?

Which has more volatility & risk, ALNT or LAB?

Is ALNT or LAB more profitable?

Does the media refer more to ALNT or LAB?

Do analysts recommend ALNT or LAB?

Do insiders and institutionals have more ownership in ALNT or LAB?

Which has stronger valuation and earnings, ALNT or LAB?

Summary

How does Standard BioTools compare to Eyepoint Pharmaceuticals?

Which has more volatility & risk, LAB or EYPT?

Does the media favor LAB or EYPT?

Is LAB or EYPT more profitable?

Do insiders and institutionals believe in LAB or EYPT?

Which has higher earnings and valuation, LAB or EYPT?

Do analysts recommend LAB or EYPT?

Summary

How does Standard BioTools compare to Transcat?

Which has more volatility and risk, TRNS or LAB?

Do insiders & institutionals hold more shares of TRNS or LAB?

Does the media prefer TRNS or LAB?

Is TRNS or LAB more profitable?

Which has better earnings and valuation, TRNS or LAB?

Do analysts recommend TRNS or LAB?

Summary

How does Standard BioTools compare to Frequency Electronics?

Which has more volatility & risk, FEIM or LAB?

Do insiders & institutionals have more ownership in FEIM or LAB?

Does the media refer more to FEIM or LAB?

Is FEIM or LAB more profitable?

Which has preferable valuation & earnings, FEIM or LAB?

Do analysts rate FEIM or LAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LAB vs. The Competition

Standard BioTools Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools